woyach on the safety profiles of btk inhibitors in cll
Published 4 years ago • 97 plays • Length 1:37Download video MP4
Download video MP3
Similar videos
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll
-
1:33
dr. woyach on ongoing research with btk inhibitors in cll
-
1:39
dr. woyach on the role of acalabrutinib in cll
-
0:38
dr. woyach on the role of btk in cll
-
1:29:05
btk inhibitors in cll: evidence-informed therapy selection, safety, and sequential care
-
5:06
evolution of btk inhibitors in cll
-
1:17
dr. woyach on btk inhibition and the mechanism of action of ibrutinib
-
1:26
adverse events associated with btkis in the treatment of waldenström’s macroglobulinemia
-
1:15
dr. flinn on the role of btk inhibitors in cll
-
1:46
dr. woyach on frontline treatment options in cll
-
1:20
dr. woyach on 3-year follow-up of acalabrutinib/obinutuzumab combo in cll
-
3:25
btk inhibitors in cll: treatment selection
-
1:14
evaluating the role of btk inhibitors in cll
-
1:26
combining btk and bcl-2 inhibitors for the treatment of cll
-
1:28
dr. ma on the utility of btk inhibitors in relapsed/refractory cll
-
0:57
dr. byrd on alacabrutinib's mechanism of action in cll
-
1:33
comparing toxicity profiles of available frontline agents in cll
-
1:00
dr. seymour on the kinase selectivity of btk inhibitors in cll
-
3:29
seizing the day with btk inhibitors in cll